Royalty Report: Drugs, Ulcer, Therapeutic – Collection: 294012

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Ulcer
  • Therapeutic
  • Pharmaceuticals
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 294012

License Grant
Licensor grants the exclusive right under the Licensed Patents and Know-How to make, use, have made and sell or have sold any Product within the Territory during the Term, including the right to make or have made outside the Territory for sale in the Territory.
License Property
Block has certain rights in and to a topical product.

Amlexanox means 2 – amino – 7 – isopropyl – 5 – oxo – SH- [1] benzopyrano – [2,3 -b] – pyridine – 3 – carboxylic acid (Takeda Code No. AA-673).

Licensed Patents means all patents and applications set forth and all Takeda Sublicensed Patents.

Product means the Formulation and any topical formulation containing Amlexanox for Dermatological Use, excluding any formulation for treatment of the cause or symptoms of oral mucositis, covered by any claim or any Licensed Patent in any country, whether or not granted.

Field of Use
The field of use is for treating aphthous ulcers containing amlexanox.
An aphthous ulcer is an ulcer that forms on the mucous membranes. They are also called aphthae, aphthosis, aphthous stomatitis and canker sores. … Recurrent aphthous ulcers are mostly a minor nuisance, but they are associated with significant health problems in some people.
Aphthous mouth ulcers (aphthae) are a common variety of ulcer that form on the mucous membranes, typically in the oral cavity (mouth). Other names for aphthous ulcers include aphthous stomatitis and canker sores.

IPSCIO Record ID: 294300

License Grant
Licensor grants the exclusive right under any Improvement Patent, if any, and Licensor Know-How, if any, now existing or subsequently developed, to make, use, have made and sell any Improvement outside the Territory during the Term, including, but not limited to, the right to make or have made the Improvement, or any part thereof, within the Territory for sale outside the Territory.
License Property
Block has certain rights in and to a topical product.

Amlexanox means 2 – amino – 7 – isopropyl – 5 – oxo – SH- [1] benzopyrano – [2,3 -b] – pyridine – 3 – carboxylic acid (Takeda Code No. AA-673).

Licensed Patents means all patents and applications set forth and all Takeda Sublicensed Patents.

Product means the Formulation and any topical formulation containing Amlexanox for Dermatological Use, excluding any formulation for treatment of the cause or symptoms of oral mucositis, covered by any claim or any Licensed Patent in any country, whether or not granted.

Amlexanox is a mucoadhesive oral paste which has been clinically proven to abort the onset, accelerate healing and resolve the pain of aphthous ulcers (canker sores). It decreases the time ulcers take to heal.

Field of Use
The field of use is for treating aphthous ulcers containing amlexanox.

IPSCIO Record ID: 3570

License Grant
The Company hereby grants to the England and Wales company an exclusive license to use the Technology to make, have made, use, develop, modify, market, sell and have sold certain rights in and to a topical product containing  amlexanox (2-amino-7-isopropyl-5-oxo-5H-[1] benzopyrano-{2,3-b}- 3-carboxylic acid for the treatment of aphthous ulcers for human use.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 372413

License Grant
The Licensor Parties grant an exclusive, world-wide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under Patent Rights and Technical information, to the extent not prohibited by other patents, in the Field of Use.
License Property
The Licensor Parties are the owners of the Method Patent and a pending patent entitled Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists and one Licensor is the owner/Sponsor of IBD FDA IND#, FDA orphan drug designation x-2969 and a pending patent for Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists.
Field of Use
The term Field of Use means development, production, use, and storage of Licensed Products, alone or in combination with other treatments, for the prevention and/or treatment of Crohn's disease and other inflammatory and ulcerative diseases of the bowel.
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.